From: T2 mapping in myocardial disease: a comprehensive review
Disease | Weighted mean T2 relaxation time at 1.5Â T | Number of studies in meta-analysis | Clinical utility of T2 mapping |
---|---|---|---|
Myocardial infarction | 58.5 ± 5.8 ms vs. 49.3 ± 2.6 ms in controls | 31 | T2 mapping differentiates acute vs. chronic myocardial infarction |
T2 mapping is used in measuring area at risk | |||
T2 mapping identifies intramyocardial hemorrhage | |||
Heart transplant | 54.6 ± 5.2 ms vs. 49.2 ± 2.5 in controls | 11 | T2 mapping is a reliable surrogate for direct tissue assessment in transplant rejection |
Prolonged T2 time may identify patients that will benefit from immunosuppression modification despite negative endomyocardial biopsy | |||
Myocarditis | 61.9 ± 11.5 ms vs. 54.4 ± 5.9 ms in controls | 19 | Prolonged T2 time corresponds to myocardial edema and inflammation on biopsy |
Abnormal T2 relaxation time has high sensitivity for diagnosing acute myocarditis | |||
Persistently prolonged T2 relaxation time is associated with increased adverse cardiac events | |||
Amyloidosis | 55.3 ± 4.2 ms vs. 50.2 ± 2.7 in controls | 2 | Local toxicity of amyloid deposits results in longer T2 time, particularly in light chain (AL) amyloidosis |
T2 mapping helps differentiate AL from ATTR amyloidosis | |||
Dilated cardiomyopathy | 62.9 ± 5.7 ms vs. 55.4 ± 3.5 in controls | 9 | T2 mapping improves early detection of dilated cardiomyopathy, prior to left ventricular dysfunction |
Shorter T2 time in patients with successful reverse myocardial remodeling after goal directed medical therapy |